Media coverage about AnaptysBio (NASDAQ:ANAB) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AnaptysBio earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.0398725166262 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of brokerages have recently weighed in on ANAB. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a research note on Friday, November 10th. Robert W. Baird restated a “buy” rating and issued a $144.00 price target (up previously from $81.00) on shares of AnaptysBio in a research report on Friday, January 19th. Wedbush restated a “positive” rating and issued a $82.00 price target (up previously from $75.00) on shares of AnaptysBio in a research report on Tuesday, November 7th. ValuEngine upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Jefferies Group initiated coverage on shares of AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. AnaptysBio presently has a consensus rating of “Buy” and an average price target of $101.89.

Shares of AnaptysBio (ANAB) opened at $111.93 on Thursday. AnaptysBio has a 1 year low of $18.15 and a 1 year high of $126.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.02. equities analysts expect that AnaptysBio will post -1.69 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/02/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-anaptysbio-anab-stock-price.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.